BRTX: AI 评分 67/100 — AI 分析 (4月 2026)

BioRestorative Therapies, Inc. is a life sciences company focused on developing regenerative medicine products using adult stem cells. Their core programs target disc/spine disease and metabolic disorders.

Key Facts: AI Score: 67/100 Sector: Healthcare

公司概况

概要：

BioRestorative Therapies, Inc. is a biotechnology firm specializing in regenerative medicine, focusing on cell-based therapies for disc/spine disorders and metabolic diseases. Their lead candidate, BRTX-100, targets painful lumbosacral disc disorders, positioning them in the evolving regenerative medicine landscape.

BRTX是做什么的？

BioRestorative Therapies, Inc., founded in 1997 and based in Melville, New York, is a life sciences company dedicated to developing regenerative medicine products and therapies. The company leverages cell and tissue protocols, primarily utilizing adult stem cells, to address unmet medical needs. BioRestorative Therapies operates two core developmental programs: the disc/spine program (brtxDisc) and the Metabolic Program (ThermoStem). The brtxDisc program features BRTX-100, an autologous cultured mesenchymal stem cell therapy, which has completed Phase 1 clinical trials for non-surgical treatment of painful lumbosacral disc disorders. The ThermoStem program is a cell-based therapy in the preclinical stage, targeting obesity and metabolic disorders using brown adipose-derived stem cells to generate brown adipose tissue. Additionally, BioRestorative Therapies provides an investigational curved needle device for targeted delivery of cells and therapeutic materials to the spine and discs. The company collaborates with industry leaders, including a research and development agreement with Rohto Pharmaceutical Co., Ltd., a research agreement with Pfizer, Inc., and a research collaboration agreement with the University of Pennsylvania. Formerly known as Stem Cell Assurance, Inc., the company rebranded to BioRestorative Therapies, Inc. in August 2011 to better reflect its focus on regenerative therapies.

BRTX的投资论点是什么？

BioRestorative Therapies presents a high-risk, high-reward investment opportunity within the regenerative medicine sector. The company's lead candidate, BRTX-100, has completed Phase 1 clinical trials, demonstrating initial safety for treating disc disorders. Successful advancement through subsequent clinical phases could significantly increase the company's valuation. The ThermoStem program, while in preclinical stages, offers potential in the growing market for obesity and metabolic disorder treatments. Key value drivers include positive clinical trial outcomes for BRTX-100 and successful preclinical development of ThermoStem. The company's collaborations with Rohto Pharmaceutical, Pfizer, and the University of Pennsylvania provide external validation and potential funding opportunities. However, the company's limited market cap of $0.00B and negative profit margin of -3304.8% highlights significant financial risks. Ongoing: The company's reliance on future funding and regulatory approvals poses substantial risks.

BRTX在哪个行业运营？

BioRestorative Therapies operates within the regenerative medicine sector, a rapidly growing field focused on developing therapies that repair or replace damaged tissues and organs. The market for regenerative medicine is projected to reach billions of dollars in the coming years, driven by aging populations and increasing prevalence of chronic diseases. The competitive landscape includes companies like BOLT, COCP, DWTX, EDSA, and EVGN, as well as larger pharmaceutical firms investing in regenerative medicine technologies. BioRestorative Therapies focuses on cell-based therapies, specifically using adult stem cells, to target disc/spine disorders and metabolic diseases.

Biotechnology

Healthcare

BRTX有哪些增长机遇？

Growth opportunity 1: Successful completion of Phase 2 and Phase 3 clinical trials for BRTX-100 represents a significant growth opportunity. Positive results could lead to regulatory approval and commercialization, addressing the market for non-surgical treatment of painful lumbosacral disc disorders. The market for minimally invasive spine treatments is expanding, driven by patient preference and technological advancements. Timeline: Phase 2 trials are expected to commence in the near term, with potential commercialization within 3-5 years pending regulatory approvals.
Growth opportunity 2: Advancing the ThermoStem program from preclinical to clinical stages offers a substantial growth opportunity in the metabolic disorder market. Obesity and related metabolic diseases are a global health crisis, creating a large unmet need for effective therapies. Successful development of ThermoStem could position BioRestorative Therapies as a key player in this market. Timeline: Clinical trials are projected to begin within the next 2-3 years, with potential commercialization in 5-7 years, contingent on positive clinical outcomes.
Growth opportunity 3: Expanding strategic partnerships with pharmaceutical companies like Rohto and Pfizer can provide access to funding, expertise, and distribution channels. These collaborations can accelerate the development and commercialization of BioRestorative Therapies' product candidates. Further partnerships with other companies in the regenerative medicine space could also broaden the company's reach and capabilities. Timeline: Ongoing, with potential for new partnerships to be established within the next 1-2 years.
Growth opportunity 4: Developing and commercializing the investigational curved needle device for targeted cell delivery to the spine and discs presents a niche market opportunity. This device could improve the precision and efficacy of cell-based therapies, providing a competitive advantage. The market for spinal delivery devices is growing, driven by demand for minimally invasive procedures. Timeline: Commercialization of the device is anticipated within the next 2-3 years, pending regulatory approvals and manufacturing scale-up.
Growth opportunity 5: Exploring new therapeutic applications for its cell-based therapies beyond disc/spine disorders and metabolic diseases represents a long-term growth opportunity. The company's expertise in adult stem cell technology could be applied to other areas of regenerative medicine, such as wound healing, cardiovascular disease, and neurodegenerative disorders. This diversification could broaden the company's market potential and reduce its reliance on specific therapeutic areas. Timeline: Long-term, with potential for new therapeutic applications to emerge within the next 5-10 years.

Market Cap of $0.00B reflects the company's early stage and speculative nature.
Gross Margin of 79.6% indicates strong potential profitability of its products, if successfully commercialized.
Profit Margin of -3304.8% highlights substantial ongoing research and development expenses and lack of revenue from commercial products.
Beta of 0.41 suggests lower volatility compared to the overall market.
Completed Phase 1 clinical trials for BRTX-100 indicates progress in disc/spine program.

BRTX提供哪些产品和服务？

Develop regenerative medicine products and therapies.
Use cell and tissue protocols involving adult stem cells.
Focus on treatments for disc/spine disease and metabolic disorders.
Develop BRTX-100 for non-surgical treatment of painful lumbosacral disc disorders.
Develop ThermoStem for obesity and metabolic disorders.
Provide an investigational curved needle device for targeted cell delivery to the spine.

BRTX如何赚钱？

Develop and license or commercialize cell-based therapies.
Generate revenue through research and development agreements.
Potentially generate revenue through sales of the curved needle device.
Seek strategic partnerships with pharmaceutical companies for funding and expertise.

Patients with painful lumbosacral disc disorders.
Patients with obesity and metabolic disorders.
Pharmaceutical companies seeking regenerative medicine technologies.
Healthcare providers specializing in spine and metabolic treatments.

Proprietary cell-based therapy technologies.
Intellectual property protection for BRTX-100 and ThermoStem.
Strategic partnerships with established pharmaceutical companies.
Expertise in adult stem cell isolation, culture, and delivery.

什么因素可能推动BRTX股价上涨？

Upcoming: Commencement of Phase 2 clinical trials for BRTX-100.
Upcoming: Preclinical data release for ThermoStem program.
Ongoing: Continued strategic partnerships and collaborations.
Ongoing: Advancements in the development of the curved needle device.

BRTX的主要风险是什么？

Potential: Unfavorable clinical trial outcomes for BRTX-100 or ThermoStem.
Potential: Regulatory delays or rejection of product approvals.
Ongoing: Competition from larger pharmaceutical companies.
Ongoing: Difficulty in securing funding for research and development.
Potential: Intellectual property challenges or infringement.

BRTX的核心优势是什么？

Proprietary cell-based therapy platforms.
Completed Phase 1 clinical trials for BRTX-100.
Strategic partnerships with Rohto, Pfizer, and University of Pennsylvania.
Experienced management team in regenerative medicine.

BRTX的劣势是什么？

Limited financial resources and market capitalization.
Negative profit margin and reliance on future funding.
Early stage of development for ThermoStem program.
Dependence on regulatory approvals for product commercialization.

BRTX有哪些机遇？

Successful completion of clinical trials for BRTX-100 and ThermoStem.
Expansion of strategic partnerships with pharmaceutical companies.
Development of new therapeutic applications for cell-based therapies.
Commercialization of the curved needle device.

BRTX面临哪些威胁？

Competition from larger pharmaceutical companies in regenerative medicine.
Regulatory hurdles and delays in clinical trials.
Unfavorable clinical trial outcomes.
Difficulty in securing funding for research and development.

BRTX的竞争对手是谁？

Bolt Biotherapeutics, Inc. — Developing immuno-oncology therapies. — (BOLT)
Cocrystal Pharma, Inc. — Focusing on antiviral drug development. — (COCP)
Datawatch Corporation — Note: This ticker appears incorrect for a biotech peer. Datawatch is a software company. — (DWTX)
Edesa Biotech, Inc. — Developing therapies for inflammatory and immune-related diseases. — (EDSA)
Evogene Ltd. — Developing agricultural biologicals and human therapeutics. — (EVGN)

Key Metrics

MoonshotScore: 67/100

Company Profile

CEO: Lance Alstodt
Headquarters: Melville, US
Employees: 11
Founded: 2012

AI Insight

AI analysis pending for BRTX

常见问题

What does BioRestorative Therapies, Inc. do?

BioRestorative Therapies, Inc. is a biotechnology company focused on developing regenerative medicine products and therapies using adult stem cells. Their primary focus is on addressing unmet medical needs in disc/spine disease and metabolic disorders. Their lead product candidate, BRTX-100, is designed for non-surgical treatment of painful lumbosacral disc disorders and has completed Phase 1 clinical trials. Additionally, they are developing ThermoStem, a cell-based therapy targeting obesity and metabolic disorders. The company also has an investigational curved needle device for targeted cell delivery.

What do analysts say about BRTX stock?

AI analysis is currently pending for BRTX. Generally, biotechnology companies in early stages of clinical development are viewed as high-risk, high-reward investments. Analyst sentiment will largely depend on clinical trial results, regulatory milestones, and the company's ability to secure funding. Key valuation metrics to consider include the potential market size for BRTX-100 and ThermoStem, the probability of success for clinical trials, and the company's cash runway.

What are the main risks for BRTX?

The main risks for BioRestorative Therapies include the inherent uncertainties of clinical development, regulatory hurdles, and competition from larger pharmaceutical companies. Unfavorable clinical trial outcomes for BRTX-100 or ThermoStem could significantly impact the company's valuation. Securing funding for ongoing research and development is also a critical risk, as the company has a negative profit margin. Furthermore, intellectual property challenges and potential infringement could pose threats to the company's proprietary technologies.